SNYNF - Revolution Medicines: Highly Differentiated Offering Gaining Traction

Summary

• Revolution Medicines, Inc. has a highly differentiated portfolio of RAS(ON) and RAS companion inhibitors that's standing up well in safety, efficacy.
• The company is well-capitalized to continue operations and clinical advancements.
• The market is recognizing Revolution Medicines' upside potential, as it has rallied back to previous highs and is testing key resistance levels.
• We rate Revolution Medicines, Inc. a buy, initial price objective $29, looking to re-rate at this point.

Investment Summary

Here at HBI, we've debated at length on how to position against unprofitable biotech names. Market dynamics have been unkind to this basket of equities this year. Hence, after extensive debate, the crowd is divided here at HBI on positioning against Revolution Medicines, Inc. ( RVMD ). However, considering all of the contributing and mitigating factors, our findings corroborate that now is an appropriate time for entry.

Our analysis will cover RVMD's treatment market and detail its financial position as it continues advancing its pipeline of highly differentiated anti-tumor compounds. Noteworthy is that RVMD signed an exclusive worldwide partnership with Sanofi ( SNY ) in 2018 to develop and commercialize therapies targeting SH2 containing protein tyrosine phosphatase-2 ("SHP2"), an oncogenic phosphatase known to promote growth and survival signaling downstream of oncologic receptor inputs. We'd note this is already starting to pull through to the company's top line growth, evidenced in Q3 FY22.

Net-net, we opine there is sufficient evidence surrounding the company's phase 1–3 assets, and the market is beginning to recognize the same. We rate RVMD a buy, seeking an initial price objective of $29.

RVMD 2-year price evolution against the S&P 500

Note: This is a high-beta offering that provides additional upside volatility within a broad market rally.

RVMD's RAS-targeting portfolio

The hallmark of the RVMD investment debate is its highly differentiated approach to inhibiting the active form or RAS, known as RAS((ON)). RVMD believes its RAS and RAS((ON)) inhibitors can be used as combination therapy with other inhibitors, such as SHP2 or mTORC1, to "attack multiple targets within the RAS pathway simultaneously to extinguish cancer cell signaling and suppress resistance mechanisms."

R AS iso forms are a group of protein molecules that regulate cellular activity , including cell growth and division , and have been found to be involved in a variety of diseases . The roles of RAS isoforms in health and disease are complex and not completely understood. Studies have shown that mutations in RAS isoforms have a causal role in cancers and other diseases, but the exact mechanism is still unclear. Simanshu and colleagues (2017) are widely cited in the nomenclature and provide a suitable "definition" [see: Abstract]:

"RAS proteins are binary switches, cycling between ON and OFF states during signal transduction. These switches are normally tightly controlled, but in RAS-related diseases, such as cancer, RASopathies, and many psychiatric disorders, mutations in the RAS genes or their regulators render RAS proteins persistently active. "

These proteins are part of the RAS super family , which includes three members : K - R as , H - R as , and N - R as . Each R AS iso form has distinct properties and functions , and mutations in any of these iso forms can lead to a variety of diseases , including cancer .

K - R as , also known as KR AS , is the most commonly studied of the R AS iso forms . It is involved in cell signaling pathways and plays a critical role in cell growth and division . Mut ations in K - R as can lead to cancer by allowing cells to grow and divide uncontroll ably . For example , mutations in K - R as are found in approximately 25 - 30 % of all pancreat ic cancer cases and 35 - 50 % of all col ore ct al cancer cases .

H - R as is another commonly studied R AS iso form . It is involved in cell signaling pathways and is essential for cell migration , which is important for wound healing and the immune response . Mut ations in H - R as have been linked to a variety of cancers , including lung , bladder , and prostate cancer .

N - R as , also known as NR AS , is the least studied of the R AS iso forms . It is involved in cell signaling pathways and is essential for cell differentiation and metabolism . Mut ations in N - R as have been linked to leukemia and melan oma .

Exhibit 1. RVMD RAS and RAS((ON)) pipeline

The company has begun clinical development for two of its RAS inhibitor drug candidates. In a Phase IIb trial, RMC-6236, an oral RAS inhibitor, is being tested on patients with tumors containing common KRAS G12 cancer mutations, including KRAS G12D [the most common RAS cancer variant causing human cancer], KRAS G12V, and KRAS-G12R. RMC-6236 is the first oral direct RAS inhibitor to target these mutations to our understanding. In a Phase I/Ib trial, RMC-6291, an oral KRASG12C inhibitor, is being tested on patients with tumors containing the KRAS G12C mutation. RMC-6291 is a highly selective inhibitor of the activated KRAS G12C variant found in lung and gastrointestinal cancers.

RVMD is also working on an oral inhibitor called RMC9805 that targets KRAS G12D. The company expects to begin clinical trials in mid-2023. We firmly believe the first round of RAS inhibitors, including RMC-6236, 6291, and 9805, could help many people with cancer caused by RAS gene mutations if safety, efficacy and reliability data holds up well.

In addition, the company is testing two RAS companion inhibitors, RMC-4630 and RMC-5552, which are designed to be used in combination with direct RAS inhibitors. Amgen, a clinical collaborator of RVMD, recently reported promising early results from its ''CodeBreak 101'' study that combined RMC-4630 with sotorasib, a KRAS G12C inhibitor. The study showed potential benefits for patients with non-small cell lung cancer who had not received KRASG12C inhibitors before. RVMD is enrolling patients in a Phase II study of this combination for KRAS G12C non-small cell lung cancer. The company also plans to study its RAS companion inhibitors with its own RAS inhibitors in the future, which could be a meaningful tailwind to its share price down the line. We'd encourage investors to stay active on this.

In terms of upcoming catalysts for RVMD in this domain, it is set to provide top-line data from its 463003 study of RMC-4630 plus sotorasib in H2 FY23', and it will present further evidence of the single-agent activity for RMC-5552 sometime next year. As above, we'd encourage investors to remain diligent in following updates for the same, in order to size in/scale-up positioning accordingly.

RVMD Q3 financials illustrate sufficient cash runway

Turning to the numbers, we note the company's recent capital budgeting initiatives have lengthened its cash runway for financing operations and additional clinical trials downstream.

RVMD successfully upsized its public offering of common stock earlier this year, raising gross proceeds of $265mm. After deducting underwriting discounts, commissions, and estimated offering expenses, RVMD generated net proceeds of approximately $248mm. This infusion of capital allowed the company to strengthen its balance sheet and end the quarter with a cash balance of $655mm, which it expects to be sufficient to fund its planned operations through 2024.

In Q 3 2022 , RV MD 's venture with San ofi resulted in an income of $ 3 . 4 mm , a large improvement from the $ 1 . 1 mm revenue made in the same quarter the year prior . A non - cash GA AP accounting adjustment lowered the collaboration income to $ 4 . 6 mm due to changes in the evaluation of the accounting transaction price and the percentage of work completed through the arrangement .

O pEx in Q 3 2022 was $ 79 . 9 mm , a 47 % growth from the preceding year . This ascent was mostly due to the larger costs of creating R MC - 6 236 and R MC - 6 291 , along with the personnel - related costs associated with the additional staff hired . Consequently , the net loss for Q 3 2022 was $ 73 . 3 mm , or $ 0 . 87 per share .

Despite these financial results, RVMD reaffirmed its previous guidance and continues to expect its full-year 2022 GAAP net loss to be between $260mm–$280mm.

RVMD technicals suggest appropriate entry, price objectives

In the absence of profitability and earnings, we use our technical studies to guide price visibility down the line.

You can see below that RVMP has formed a 16-week cup and handle that has seen shares cross the 50DMA and 250DMA for the past 7 weeks.

At the same time, the volume trend has been ascending on average since the 50DMA and 250DMA cross. Shares now test previous highs and a break above the neckline here suggests further upside capture is warranted in our opinion.

Exhibit 2. RVMD 18-month weekly price evolution, 16-week cup and handle with 50DMA/250DMA cross.

Consequently we believe the rally has more legs to run yet, and have additional upside targets to $25.5 then $29, or ~18.4% upside potential as an initial price objective.

In combination with the above chart studies we believe now is a good time for entry. We look forward to any further potential price action to the upside, as we are confident this will lead to the formation of additional targets above $29.

Exhibit 3. Upside targets to $25.5 then $29, suggesting further upside capture is warranted.

In short

We rate RVMD a buy given improving market data, technical studies and the company's highly differentiated offering of RAS((ON)) and RAS companion inhibitors. Already the market has begun to reward Revolution Medicines stock following developments in Q3 and there are multiple inflection points identified for 2023. With this in mind, we rate Revolution Medicines, Inc. a buy, initial price objective of $29.

For further details see: